BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
ZYNYZ (retifanlimab-dlwr) by Incyte is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYNYZ (retifanlimab-dlwr) is a monoclonal antibody that blocks programmed death receptor-1 (PD-1), enabling the immune system to recognize and attack cancer cells. It is administered intravenously as an injectable biologic. The drug represents Incyte's entry into the competitive PD-1 inhibitor oncology space.
Peak
ZYNYZ is at peak lifecycle with moderate competitive pressure (30/100), indicating an established but challenged market position requiring strategic portfolio defense and efficiency gains.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZYNYZ careers center on defending market share in a crowded PD-1 space and driving uptake against entrenched competitors. Professionals on this product will focus on differentiation, payer negotiation, and patient access rather than greenfield launch innovation.
Brand Manager
Worked on ZYNYZ at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.